跳至主要内容
临床试验/NCT03133013
NCT03133013已完成不适用

A Study on Realization of Objective Evaluation Method of Depression Using Sleep EEG

Stanford University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2017年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
1
主要终点
Assist in the diagnosis of depression

研究概览

简要总结

The purpose of this study is to test the ability of a brainwave measurement device (SLEEPSCOPE) in identifying and assisting in the diagnosis of depression. The brainwave data from individuals with untreated depression and healthy participants will be collected and analyzed. The ability to obtain brainwave data from individuals in their homes while they're sleeping would represent a significant advance in depression research.

详细描述

The purpose of study is to collect and analyze human sleeping brainwave data, to better understand depression in humans.

First visit:

  • Informed consent procedures, including explanation of research background, purpose, details of implementation, and study benefits and risks
  • Interview with questionnaires (MINI International Psychiatric Interview, Hamilton Rating Scale for Depression, Beck Depression Inventory, Patient Health Questionnaire for Depression [PHQ-9]), physical examination.
  • Urine drug sample for screening of controlled substances.
  • Inform participants that those qualifying will be informed whether or not to proceed with second visit

Second visit:

  • Explanation of EEG measurement (placement of two electrodes, one on the forehead and one behind the ear)
  • Sleep diary provided for participant to complete at home for each night until third visit
  • Distribution of EEG devices for home use
  • EEG measurement conducted at participant's residence for three nights of stable sleep-wake cycles

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
30 Years 至 59 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Individuals with Untreated Depression:
  • •16 men and 16 women aged from 30 to 59 years, with an approximate ethnic balance of 10 Asian, 3 White and 3 other ethnicity for each gender, whom are diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and DSM-5 criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9).
  • •Healthy Participants:
  • •16 men and 16 women age-, ethnic-, and gender-matched healthy participants to the cohort with untreated depression, with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and DSM-5 criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9).

排除标准

  • •Participants corresponding to any of the following conditions are considered ineligible for the trial.
  • •Diagnosed with epilepsy or other organic brain disorder.
  • •Medical conditions resulting in depressive symptoms such as hypothyroidism, Cushing's disease, systemic lupus erythematosus; neurological conditions resulting in depressive symptoms such as Parkinson's disease, Huntington's disease, multiple sclerosis
  • •Patients with suspected sleep apnea, based on symptoms and a BMI of 30 or greater
  • •Prescribed interferon regularly with stimulants, opioid drugs (Ritalin, Opioid, etc.) and steroids
  • •Repetitive thoughts of death, current thoughts about suicide, suicide attempts, or a suicide plan
  • •Tested positive to controlled substance use by a urine drug screening before commencement of testing
  • •Current or past drug or alcohol dependence
  • •Shift work or rotating work schedule
  • •Nursing, pregnant or planning to become pregnant
  • •Participating in other clinical trials

研究组 & 干预措施

Individuals with Untreated Depression

Experimental

32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.

干预措施: SLEEPSCOPE (Device)

Healthy Participants

Other

32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.

干预措施: SLEEPSCOPE (Device)

结局指标

主要结局

Assist in the diagnosis of depression

时间窗: 1 month

The SLEEPSCOPE data will be analyzed to determine if it can help to identify individuals with depression

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Clete A. Kushida

Professor

Stanford University

研究点 (1)

Loading locations...

相似试验